Compare Medtronic PLC (MDT) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Raymond James Financial, Inc. — how do they compare? Medtronic PLC trades at $90.61 (market cap $116.07B), while Raymond James Financial, Inc. trades at $179.97 (market cap $34.63B). The key difference: Medtronic PLC is far larger — about 3.4× Raymond James Financial, Inc.'s market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| MDT | RJF | |
|---|---|---|
Market Cap | $116.07B | $34.63B |
Sector | Health | Financials |
52-Week High | $105.35 | $180.55 |
52-Week Low | $73.75 | $140.89 |
Enterprise Value | $134.82B | — |
Dividend Yield | 3.18% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.
The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.
Raymond James Financial (RJF) trades at $181.18, up 1.17% with strong technical momentum including a golden cross formation. The company reported record Q3 2026 earnings of $3.14 per share, beating estimates by 7.2%, driven by 16% revenue growth to $3.93 billion. Analyst consensus remains positive with 44% buy ratings and a $183.75 price target, slightly above current levels. The stock shows bullish moving average signals while RSI indicates potential overbought conditions near-term.
RJF demonstrates solid fundamental growth with consistent earnings beats and expanding profit margins, though valuation appears fair at current levels. Key risks include market sensitivity to capital markets performance and competitive advisor recruitment landscape. The technical setup suggests near-term resistance around $182, while fundamental strength supports longer-term upside potential if revenue momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
